{"filing":{"accession_number":"0001628280-26-038058","cik":"0001854270","ticker":"SNTI","company_name":"Senti Biosciences Holdings, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"snti-20260520.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026038058/snti-20260520.htm"},"events":[{"id":9148,"run_id":8030,"accession_number":"0001628280-26-038058","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Senti Biosciences issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026, pursuant to a Securities Purchase Agreement. The convertible notes are dilutive securities that can convert to equity, materially affecting shareholder equity and voting power.","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1653,"accession_number":"0001628280-26-038058","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Senti Biosciences issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026, pursuant to a Securities Purchase Agreement. Convertible notes are inherently dilutive securities that can convert to equity, and the issuance of $10 million in principal amount represents a material capital raise that would affect shareholder equity and voting power. This is a classic dilutive issuance event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:35:24.980102+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1654,"accession_number":"0001628280-26-038058","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation by incorporating Item 1.01 by reference. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined. Item 1.01 typically covers material acquisitions, dispositions, or business combinations (ma_activity), but could also involve debt issuance, lease arrangements, or other financial obligations. Given the ambiguity and the cross-reference structure, classifying as other_material is most appropriate pending visibility into Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:35:24.980102+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1653,"accession_number":"0001628280-26-038058","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Senti Biosciences issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026, pursuant to a Securities Purchase Agreement. Convertible notes are inherently dilutive securities that can convert to equity, and the issuance of $10 million in principal amount represents a material capital raise that would affect shareholder equity and voting power. This is a classic dilutive issuance event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:35:24.980102+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-05-26"},{"id":1654,"accession_number":"0001628280-26-038058","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation by incorporating Item 1.01 by reference. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined. Item 1.01 typically covers material acquisitions, dispositions, or business combinations (ma_activity), but could also involve debt issuance, lease arrangements, or other financial obligations. Given the ambiguity and the cross-reference structure, classifying as other_material is most appropriate pending visibility into Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:35:24.980102+00:00","company_name":"Senti Biosciences Holdings, Inc.","ticker":"SNTI","filing_date":"2026-05-26"}]}